Review



il13ra2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems il13ra2
    Il13ra2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 37 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il13ra2/product/R&D Systems
    Average 93 stars, based on 37 article reviews
    il13ra2 - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    Sino Biological il13rα2
    Il13rα2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il13rα2/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    il13rα2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    86
    Thermo Fisher gene exp il13ra2 mm00515166 m1
    Gene Exp Il13ra2 Mm00515166 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp il13ra2 mm00515166 m1/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    gene exp il13ra2 mm00515166 m1 - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    99
    Beyotime il13ra2 antibody
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Il13ra2 Antibody, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il13ra2 antibody/product/Beyotime
    Average 99 stars, based on 1 article reviews
    il13ra2 antibody - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    93
    Proteintech anti il13ra2
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Anti Il13ra2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti il13ra2/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti il13ra2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    R&D Systems il13ra2
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Il13ra2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il13ra2/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    il13ra2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc il13ra2
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Il13ra2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il13ra2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    il13ra2 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    98
    Thermo Fisher gene exp il13ra2 hs00152924 m1
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Gene Exp Il13ra2 Hs00152924 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp il13ra2 hs00152924 m1/product/Thermo Fisher
    Average 98 stars, based on 1 article reviews
    gene exp il13ra2 hs00152924 m1 - by Bioz Stars, 2026-05
    98/100 stars
      Buy from Supplier

    93
    R&D Systems anti il13ra2
    Analysis of <t>IL13RA2's</t> Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Anti Il13ra2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti il13ra2/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti il13ra2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    Analysis of IL13RA2's Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

    doi: 10.1016/j.mtbio.2026.102823

    Figure Lengend Snippet: Analysis of IL13RA2's Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

    Techniques: Quantitative Proteomics, Expressing

    Expression of IL13RA2 in Glioblastoma ( a ) IL13RA2 mRNA expression levels in normal brain tissues (n = 6), LGG tissues (n = 10), and HGG tissues (n = 10) detected by qRT-PCR (normalized to GAPDH, 2 ^(−ΔΔCT) method; ∗ P < 0.05 ). ( b ) RT-qPCR detection of IL13RA2 mRNA expression levels in three GBM cell lines and normal glial cells HEB, data are presented as the mean ± SD of three independent experiments. (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). ( c-d ) Western blot analysis of IL13RA2 protein expression (molecular weight ∼55 kDa; GAPDH [37 kDa] as internal control; quantitative analysis by ImageJ software, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001). ( e ) Immunofluorescence localization of IL13RA2 (red fluorescence) in cells (DAPI: blue, nuclear staining; laser confocal microscopy, non-permeabilized condition; scale bar = 50 μm; HEB cells show negligible IL13RA2 signal, while GBM cells exhibit strong membrane-localized fluorescence). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

    doi: 10.1016/j.mtbio.2026.102823

    Figure Lengend Snippet: Expression of IL13RA2 in Glioblastoma ( a ) IL13RA2 mRNA expression levels in normal brain tissues (n = 6), LGG tissues (n = 10), and HGG tissues (n = 10) detected by qRT-PCR (normalized to GAPDH, 2 ^(−ΔΔCT) method; ∗ P < 0.05 ). ( b ) RT-qPCR detection of IL13RA2 mRNA expression levels in three GBM cell lines and normal glial cells HEB, data are presented as the mean ± SD of three independent experiments. (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). ( c-d ) Western blot analysis of IL13RA2 protein expression (molecular weight ∼55 kDa; GAPDH [37 kDa] as internal control; quantitative analysis by ImageJ software, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001). ( e ) Immunofluorescence localization of IL13RA2 (red fluorescence) in cells (DAPI: blue, nuclear staining; laser confocal microscopy, non-permeabilized condition; scale bar = 50 μm; HEB cells show negligible IL13RA2 signal, while GBM cells exhibit strong membrane-localized fluorescence). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Molecular Weight, Control, Software, Immunofluorescence, Fluorescence, Staining, Confocal Microscopy, Membrane

    In Vitro Binding of A2b11 Peptide to IL13RA2 Protein ( a ) Immunofluorescence colocalization analysis (A2b11 labeled with FAM: green fluorescence; IL13RA2 antibody: red fluorescence; DAPI: blue, nuclear staining; scale bar = 50 μm; Pearson's correlation coefficients: U251MG = 0.867 ± 0.015, U373MG = 0.920 ± 0.026, U87MG = 0.933 ± 0.015, mean ± SD, n = 3 independent experiments). ( b ) SPR sensorgram of IL13RA2 protein immobilization on CM5 chip (activation by EDC/NHS, deactivation by ethanolamine-HCl; immobilization level = 4558.8 RU). ( c ) SPR binding sensorgram of A2b11 peptide (analyte, concentration = 100 μM, sequence = WALRVKAG) with immobilized IL13RA2 (binding response = 12.7 RU; data analyzed by Biacore software). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

    doi: 10.1016/j.mtbio.2026.102823

    Figure Lengend Snippet: In Vitro Binding of A2b11 Peptide to IL13RA2 Protein ( a ) Immunofluorescence colocalization analysis (A2b11 labeled with FAM: green fluorescence; IL13RA2 antibody: red fluorescence; DAPI: blue, nuclear staining; scale bar = 50 μm; Pearson's correlation coefficients: U251MG = 0.867 ± 0.015, U373MG = 0.920 ± 0.026, U87MG = 0.933 ± 0.015, mean ± SD, n = 3 independent experiments). ( b ) SPR sensorgram of IL13RA2 protein immobilization on CM5 chip (activation by EDC/NHS, deactivation by ethanolamine-HCl; immobilization level = 4558.8 RU). ( c ) SPR binding sensorgram of A2b11 peptide (analyte, concentration = 100 μM, sequence = WALRVKAG) with immobilized IL13RA2 (binding response = 12.7 RU; data analyzed by Biacore software). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

    Techniques: In Vitro, Binding Assay, Immunofluorescence, Labeling, Fluorescence, Staining, Activation Assay, Concentration Assay, Sequencing, Software